Any feedback?
Literature summary for 3.4.14.5 extracted from
- Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug (2007), Diabetes Obes. Metab., 9, 153-165.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | major clinical trials with DPP-IV inhibitors as monotherapy and as add-on therapy in patients with type 2 diabetes. The magnitude of HbA1c reduction with DPP-IV inhibitors depends upon the pretreatment HbA1c values, but there seems to be no change in body weight, and very low rates of hypoglycaemia and gastrointestinal disturbance with these agents. DPP-IV inhibitors represent a major class of oral antidiabetic drug and their metabolic profile offers a number of unique clinical advantages for the management of type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism | Homo sapiens |  |
| vildagliptin | highly effective antihyperglycaemic agent that augments insulin secretion and reduces glucagon secretion via glucose-dependent mechanism | Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| dipeptidyl peptidase-IV | - |
Homo sapiens |
| DPP-IV | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
